Sanofi Consumer Healthcare India Ltd Declines 1.56%: 4 Key Technical Signals Shaping the Week

25 minutes ago
share
Share Via
Sanofi Consumer Healthcare India Ltd’s stock declined by 1.56% over the week ending 25 September 2026, closing at Rs.3,953.15 compared to Rs.4,015.85 the previous Friday. This underperformance contrasted with the Sensex’s smaller 0.76% fall, reflecting persistent technical weakness and valuation concerns amid mixed market signals and sector pressures.

Key Events This Week

21 Sep: Stock opens at Rs.4,003.95, down 0.30%

22 Sep: Technical setbacks amid mixed momentum signals

23 Sep: Bearish momentum intensifies with technical downgrade

24 Sep: Mild bullish volume contrasts with bearish price action

25 Sep: Stock hits 52-week low of Rs.3,940

Week Open
Rs.4,015.85
Week Close
Rs.3,953.15
-1.56%
Week High
Rs.4,006.05
vs Sensex
-0.80%

21 September 2026: Week Opens with Mild Decline Amid Positive Sensex

Sanofi Consumer Healthcare India Ltd began the week at Rs.4,003.95, down 0.30% from the previous close of Rs.4,015.85. This decline occurred despite the Sensex gaining 0.46% to close at 35,787.64, signalling early divergence between the stock and the broader market. Trading volume was moderate at 271 shares, with the stock price hovering closer to its 52-week low of Rs.3,950.50 than its high of Rs.5,241.35, indicating ongoing pressure on the stock.

22 September 2026: Technical Setbacks Amid Mixed Momentum Signals

The stock continued its downward trajectory, closing at Rs.3,988.90, a 0.38% decline. Technical analysis revealed a shift from bearish to mildly bearish momentum, with daily moving averages remaining negative. While weekly RSI and monthly On-Balance Volume (OBV) suggested some underlying buying interest, the overall technical landscape remained cautious. The stock’s proximity to its 52-week low and underperformance relative to the Sensex, which fell 0.32% that day, underscored the challenges faced.

Momentum just kicked in! This Small Cap from the Auto - Trucks sector entered our list with explosive short-term signals. Catch the wave while it's still building!

  • - Fresh momentum detected
  • - Explosive short-term signals
  • - Early wave positioning

Catch the Wave Now →

23 September 2026: Bearish Momentum Intensifies with Technical Downgrade

On 23 September, the stock closed at Rs.4,006.05, rebounding slightly by 0.43%, yet technical indicators worsened. The MarketsMOJO grade was downgraded from Hold to Sell on 10 August 2026, reflecting deteriorating momentum. The weekly MACD remained firmly bearish, and Bollinger Bands indicated continued downward pressure. Despite a bullish weekly RSI hinting at short-term oversold conditions, the stock’s underperformance persisted, closing below the Sensex’s 0.56% gain that day.

24 September 2026: Mixed Signals as Volume Shows Mild Bullishness

The stock slipped to Rs.3,972.75, down 0.83%, amid a volatile market where the Sensex fell 1.62%. Technical momentum shifted from bearish to mildly bearish, with weekly RSI turning bullish and On-Balance Volume showing mild accumulation. However, daily moving averages and Bollinger Bands remained bearish, suggesting resistance to sustained recovery. The divergence between volume and price momentum highlighted the complex technical environment facing the stock.

Sanofi Consumer Healthcare India Ltd or something better? Our SwitchER feature analyzes this small-cap stock and recommends superior alternatives based on fundamentals, momentum, and value!

  • - SwitchER analysis complete
  • - Superior alternatives found
  • - Multi-parameter evaluation

See Smarter Alternatives →

25 September 2026: Stock Hits 52-Week Low Amid Persistent Weakness

Sanofi Consumer Healthcare India Ltd’s share price fell to a fresh 52-week low of Rs.3,940, closing the week at Rs.3,953.15, down 0.49% on the day. This marked a significant downturn amid broader sector pressures, with the stock trading below all key moving averages and technical indicators signalling sustained bearish momentum. Despite a bullish weekly RSI and mild bullishness in monthly OBV, the stock’s valuation metrics, including a high price-to-book ratio of 23.9 and a PEG ratio of 2.1, raised concerns about growth prospects. Institutional investors hold 20.46%, reflecting some confidence despite the decline.

Date Stock Price Day Change Sensex Day Change
2026-09-21 Rs.4,003.95 -0.30% 35,787.64 +0.46%
2026-09-22 Rs.3,988.90 -0.38% 35,672.04 -0.32%
2026-09-23 Rs.4,006.05 +0.43% 35,870.78 +0.56%
2026-09-24 Rs.3,972.75 -0.83% 35,291.38 -1.62%
2026-09-25 Rs.3,953.15 -0.49% 35,353.29 +0.18%

Key Takeaways

Technical Weakness Persists: The stock’s weekly MACD and daily moving averages remained bearish throughout the week, with Bollinger Bands indicating continued downward pressure. The downgrade to a Sell grade by MarketsMOJO reinforces the cautious technical outlook.

Mixed Momentum Signals: Weekly RSI showed intermittent bullish signals suggesting short-term oversold conditions, while monthly OBV indicated some accumulation. However, these were insufficient to reverse the overall negative trend.

Valuation Concerns: Despite strong management efficiency reflected in a 69.3% ROE, the stock’s high price-to-book ratio of 23.9 and PEG ratio of 2.1 suggest stretched valuations, contributing to investor scepticism.

Relative Underperformance: The stock declined 1.56% over the week, underperforming the Sensex’s 0.76% fall. It also hit a 52-week low, highlighting ongoing challenges amid sector headwinds.

Conclusion

Sanofi Consumer Healthcare India Ltd’s performance over the week ending 25 September 2026 was marked by persistent technical weakness and valuation pressures, culminating in a 52-week low close at Rs.3,953.15. While some technical indicators hinted at short-term buying interest, the dominant bearish momentum and downgrade to a Sell rating underscore the cautious sentiment prevailing among investors. The stock’s underperformance relative to the Sensex and its stretched valuation metrics suggest that further downside risks remain. Investors should monitor evolving technical signals and sector developments closely before considering exposure to this small-cap pharmaceutical player.

{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News